A pilot study of a novel, collagen-based substitute for donated corneal tissue has detected an unexpectedly strong efficacy signal in 20 patients with advanced corneal disease and has set the stage for a larger randomized control trial that could lead to regulatory approval. Fourteen of the phase I trial participants were legally blind prior to undergoing implantation of the device; none were at two years’ follow-up.